Clinical proof of concept for small molecule mediated inhibition of IL-17 in psoriasis.
Saved in:
| Title: | Clinical proof of concept for small molecule mediated inhibition of IL-17 in psoriasis. |
|---|---|
| Authors: | Warren RB; Dermatology Centre, Northern Care Alliance NHS Foundation Trust, Manchester, United Kingdom.; NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom., Hunter HJA; Dermatology Centre, Northern Care Alliance NHS Foundation Trust, Manchester, United Kingdom.; NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom.; Medicines Evaluation Unit, Manchester, United Kingdom., Papp KA; Alliance Clinical Research and Probity Medical Research, Waterloo, Ontario, Canada.; Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada., Gordon KB; Dermatology, Medical College of Wisconsin, Wauwatosa, Wisconsin, United States of America., Tang MT; DICE Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, South San Francisco, California, United States of America., Enejosa JV; DICE Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, South San Francisco, California, United States of America., Huang KC; DICE Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, South San Francisco, California, United States of America., Raha D; DICE Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, South San Francisco, California, United States of America., Batugedara HM; DICE Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, South San Francisco, California, United States of America., Skinner C; DICE Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, South San Francisco, California, United States of America., Kobel PA; DICE Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, South San Francisco, California, United States of America., Rademacher PM; DICE Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, South San Francisco, California, United States of America., Ghilardi N; DICE Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, South San Francisco, California, United States of America., Fatheree P; DICE Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, South San Francisco, California, United States of America., Jacobsen JR; DICE Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, South San Francisco, California, United States of America., Lu TT; DICE Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, South San Francisco, California, United States of America. |
| Source: | PloS one [PLoS One] 2026 Jan 23; Vol. 21 (1), pp. e0341049. Date of Electronic Publication: 2026 Jan 23 (Print Publication: 2026). |
| Publication Type: | Journal Article; Clinical Trial, Phase I; Randomized Controlled Trial |
| Journal Info: | Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1932-6203 |
|---|---|
| DOI: | 10.1371/journal.pone.0341049 |
